John Norris, MD
Allergy & Immunology · Charlotte, NCNPI 1114952322
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $148,147 of the $198,252 with a category attached, or 74.7%. 43 manufacturers reported payments, led by GSK at 48.9% of the total. Reporting peaked in 2022 at $50,478 and has fallen 63.4% since, to $18,452 in 2025. Among allergy & immunology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,334 payments — averaging $148.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$97K
- Regeneron Healthcare Solutions, Inc.$39K
- Bristol Myers Squibb$17K
- AstraZeneca$17K
- Sanofi$11K
- Pfizer$2K
- plus $15K from 37 others
What the payments were for
- Consulting fees$18,2979%
- Speaking & faculty fees$148,14775%
- Travel & lodging$2,4091%
- Food & beverage$29,27115%
- Education$1280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$198,252 in reported general payments places this provider in the 90th percentile of 140 allergy & immunology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrladeyoBerotralstat Hydrochloride | 12 | $528,931 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 47 | $378,055 |
| HyqviaIgg/Hyaluronidase,recombinant | 39 | $288,291 |
| TezspireTezepelumab-Ekko | 45 | $184,066 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 164 | $127,080 |
| Dupixent PenDupilumab | 31 | $118,244 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 11 | $112,173 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 14 | $74,149 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $65,081 |
| XolairOmalizumab | 11 | $55,684 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 18 | $51,770 |
| Dupixent SyringeDupilumab | 13 | $50,622 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 49 | $32,447 |
| Breo ElliptaFluticasone/Vilanterol | 45 | $20,347 |
| Epinephrine | 52 | $12,607 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru, Hyqvia, Gammagard Liquid | $1,836 | $731,42699 claims |
| Biocryst US Sales Co., LLCOrladeyo | $679 | $528,93112 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $16,745 | $221,955110 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $96,866 | $151,258220 claims |
| CSL BehringHizentra, Privigen | $925 | $125,91932 claims |
| Hikma Pharmaceuticals USAEpinephrine, Ryaltris | $103 | $15,66863 claims |
| Optinose US, Inc.Xhance | $1,233 | $9,78412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 140 allergy & immunology providers in North Carolina.
Other allergy & immunology in Charlotte
- Maeve OconnorCharlotte$2.2M
- Roopen PatelCharlotte$257K
- Vandana PatelCharlotte$105K
- Jennifer CaicedoCharlotte$50K
- Richard CollinsCharlotte$28K
- Shannon ChadhaCharlotte$22K
- Emily LangleyCharlotte$21K
- Bailee GilchristCharlotte$20K
- Susan HungnessCharlotte$17K
- Michael LapuenteCharlotte$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.